To dissect the molecular basis of the neuroimmune response associated with the genesis of inflammatory (nociceptive) pain, we constructed a herpes simplex virus-based gene transfer vector to express the antiinflammatory cytokine interleukin-10 (IL-10), and used it to examine the effect of IL-10 expression in activated microglial cells in vitro, and in inflammatory pain in vivo. IL-10 reduced the phosphorylation of p38 mitogen-activated protein kinase (MAPK) and decreased the expression of full-length membrane spanning tumor necrosis factor-a (mTNFa) following lipopolysaccharide stimulation of microglia in vitro. IL-10 also reduced intracellular cleavage of mTNFa and release of the soluble cleavage product sTNFa. Similar effects on TNFa expression were observed when the cells were pretreated with a p38 MAPK inhibitor. In animals, injection of a dilute solution of formalin in the skin resulted in an increase in mTNFa in spinal dorsal horn, without detectable sTNFa. Local release of IL-10 achieved by gene transfer reduced the number of spontaneous flinches in the early and delayed phases of the formalin test of inflammatory pain. The effect of IL-10 on nocisponsive behavior correlated with a block in phosphorylation of p38 and reduced expression of 26 kDa mTNFa in spinal microglia. The results emphasize the key role played by membrane TNFa in the spinal neuroimmune response in pain caused by peripheral inflammation.
Introduction
Tumor necrosis factor-a (TNFa) plays a central role in initiating inflammatory reactions of the innate immune system, inducing the production of the proinflammatory cytokines interleukin (IL)-1b and IL-6, activating the expression of adhesion molecules and stimulating inflammatory cells. It has been known for some time that peripheral inflammatory conditions resulting in heightened pain sensitivity are characterized by an early release of TNFa at the site of inflammation. 1 Direct application of TNFa to peripheral nerve induces spontaneous electrophysiologic activity in neurons of the dorsal root ganglion (DRG), [2] [3] [4] and subcutaneous or epineurial application of TNFa produces nocisponsive behaviors. 5, 6 A substantial body of evidence suggests that neuroimmune activation of glial cells in the dorsal horn of spinal cord results in the release of proinflammatory cytokines and plays an important role in facilitation of nociceptive neurotransmission and the development of chronic pain. [7] [8] [9] [10] Expression of TNFa in the dorsal horn of spinal cord is increased in models of central 11 and peripheral 12 neuropathic pain. Proinflammatory cytokines are increased in conditions characterized by peripheral inflammation 13 and have been shown to enhance nociceptive neurotransmission at the spinal level. 13, 14 IL-10, a prototypical antiinflammatory cytokine, was initially characterized as a cytokine synthesis inhibitory factor because of its potent ability to downregulate the synthesis of proinflammatory cytokines. IL-10 inhibits the expression of IL-1b, TNFa and suppresses the activity of proinflammatory Th1 cells. Intrathecal administration of IL-10 protein, or of adenovirus or adeno-associated virus-based vectors that produce IL-10, reduces painrelated behaviors in models of neuropathic pain. 15, 16 In previous studies we have shown that vectors constructed from nonreplicating herpes simplex virus (HSV) recombinants can be used effectively to transfer genes into DRG neurons from subcutaneous inoculation, and that release of inhibitory neurotransmitters or antiinflammatory proteins from the central afferent terminals of transduced DRG neurons in vivo can be used to modulate pain-related behaviors. 11, 12, 17, 18 In this study, we used a nonreplicating HSV vector constructed to express and release IL-10 in the formalin model of inflammatory pain. We report that prolonged expression and transport of IL-10 by primary afferents to dorsal horn prevents the activation of p38 mitogen-activated protein kinase (MAPK) and decreases expression of mTNFa in microglia with concomitant reduction in pain-related behaviors during the delayed phase of the formalin test. The results implicate microglial mTNFa in spinal neuroimmune activation in inflammatory pain.
Results
We have previously demonstrated that subcutaneous inoculation of an HSV vector can be used to transduce DRG in vivo to deliver transgene products to dorsal horn of spinal cord. 11, 12, 17, 18 For the purposes of this study we constructed a non-replicating vector (QHIL10) that contains two copies of a hemagglutinin (HA)-tagged rat IL-10 gene, each under the control of the human cytomegalovirus immediate-early promoter (HCMV IEp; Figure 1a ). Control vector QHGFP contains two copies of the green fluorescent protein (GFP) gene under the control of the same promoter (Figure 1b) . In a preliminary study we confirmed that transfection of dissociated primary DRG neurons in vitro with vector QHIL10 at multiplicity of infection (MOI) of 1 resulted in robust expression and release of IL-10 ( Figures 2a-d) . Subcutaneous inoculation in the plantar surface of the hind paw of rats with 30 ml of QHIL10 (1 Â 10 9 PFU per ml) resulted in expression of IL-10 in lumbar L4-L5 DRG ( Figure 2e ) and transport of vector-derived IL-10 protein to the central terminals of the pseudounipolar DRG axon in the dorsal horn of the lumbar spinal cord (Figure 2f ).
IL-10 attenuates the increase in expression and release of TNFa following lipopolysaccharide
To examine the biological effect of vector-derived IL-10 on microglia in vitro, we used a microglial (HAPI) cell line that has been well characterized and exhibits substantial similarities to primary central nervous system (CNS) microglia. 19 HAPI cells, like native microglia, express the cell surface complement receptor 3 detected by OX42 (CD11b) antibody ( Figure 3a) ; we confirmed that the IL-10 receptor was present as well ( Figure 3b) . To examine the effects of IL-10, we confirmed that HAPI cells transduced in vitro by QHIL10 release substantial amounts of IL-10 into the medium as detected by enzyme-linked immunosorbent assay (ELI-SA) (Figure 3c ). IL-10 expressed in the cell lysate was recognized by both anti-HA and anti-IL-10 antibodies, confirming its identity as a product of the transgene (Figure 3d mTNFa in inflammatory pain Z Zhou et al these samples. TNFa immunoreactivity in the dorsal horn was found in restricted zones in activated microglia, identified by OX42 immunostaining (Figure 7g ). Release of IL-10 in dorsal horn achieved by inoculation of vector QHIL10 blocked the increase in mTNFa expression (Figures 7a-d ) and the p-p38 MAPK (Figures 7e and f) .
Discussion
These studies demonstrate that vector-mediated expression of IL-10 in DRG resulting in the delivery of IL-10 to the dorsal horn reduces inflammatory pain and prevents the activation of p38 MAPK and expression of mTNFa in dorsal horn of spinal cord. The results suggest that the 26 kDa transmembrane form of mTNFa is the predominant form of that protein expressed in dorsal horn in the setting of a neuroimmune response induced by inflammatory pain originating at a distant site. TNFa plays a critical role in the development of both inflammatory and neuropathic pain. 20 Peripherally, endoneurial or intramuscular injection of TNFa results in pain-related behaviors, 21, 22 and nerve injury results in increased expression of TNFa in DRG.
23-25
TNFa expression is increased in the lumbar spinal cord after thoracic spinal cord injury that results in central neuropathic pain. 11 While the early phase of flinching after formalin administration results from C-fiber activation caused by the peripheral stimulus, the late phase of flinching represents the windup phenomenon. 26 Spinal cord glia are activated in the nociceptive response to formalin injection, 27 and our results indicate that spinal mTNFa plays a critical role in the development of pain.
TNFa is initially expressed as a 26 kDa type II transmembrane protein (mTNFa) that can be cleaved by a TNFa convertase both intracellularly 28 and on the cell surface 29 to release the 17 kDa sTNFa. 28 These Figure 4 Tumor necrosis factor-a (TNFa) mRNA and protein in HAPI cells transduced with QHGFP or QHIL10 and exposed to lipopolysaccharide (LPS) determined by reverse transcription (RT)-PCR (a) and western blot (c). The amount of mRNA was quantified by relative optical density (b) and the sum of 17 and 26 kDa protein bands quantified by chemiluminescence (d), normalized to b-actin mRNA and protein levels, respectively. The amount of sTNFa released into the culture medium was determined by ELISA (DY510, R&D Systems; e). The data represent the results of three independent experiments. Mean7s.e.m.; **Po0.01. Figure 5 Tumor necrosis factor-a (TNFa) mRNA and TNFa protein (mTNFa plus sTNFa) in HAPI cells pretreated with 10 mM SB202190 for 30 min prior to addition of lipopolysaccharide (LPS) determined by RT-PCR (a) and western blot (c). The amount of mRNA was quantified by relative optical density (b) and the sum of the 17 and 26 kDa protein bands quantified by chemiluminescence (d), normalized to b-actin mRNA and protein levels, respectively. sTNFa released in the culture medium by ELISA (e). p-p38 and p38 protein (western blot) in HAPI cells transduced with QHGFP or QHIL10 and exposed the LPS (f). Ratio of p-p38 to p38-determined chemiluminescence (g). Data presented represent the results of three independent experiments. Mean7s.e.m.; *Po0.05; **Po0.01. mTNFa in inflammatory pain Z Zhou et al conversion steps are critical for the release of the bioactive sTNFa, but mTNFa can mediate an inflammatory response independent of cleavage or the production of sTNFa. 30, 31 In our in vivo study of inflammatory pain, we found a marked increase in full-length mTNFa in the spinal dorsal horn 45 min after formalin injection, but sTNFa was not detected. mTNFa colocalized with OX42 at restricted sites in microglia in the spinal cord. In contrast, direct exposure of microglia to a potent inflammatory stimulus (LPS) resulted in increased expression of mTNFa and a concomitant increase in cleavage, beginning in the intracellular compartment, and the release of sTNFa. This suggests that neuroimmune activation in the spinal cord in vivo-occurring distant from the site of injury-differs in important ways from the direct inflammatory response to tissue injury, and that mTNFa plays a critical role in that response.
p38 MAPK plays an important role in the cellular response to environmental stress and inflammatory triggers including LPS. In models of inflammatory pain, p-p38 in microglia is a critical early marker of central neuroimmune activation. 32 In mucosal cells IL-10 downregulates the synthesis of TNFa by reducing RNA translation through inhibition of the activating p38 MAPK pathway. 33 In microglial cells in vitro, we demonstrated that inhibition of p-p38 by a specific inhibitor blocks the increase in TNFa in response to LPS, and that IL-10 blocks the p-p38 and consequent synthesis and release of TNFa in response to the same stimulus. In vivo, IL-10 similarly blocked the p-p38 and mTNFa in inflammatory pain Z Zhou et al synthesis of mTNFa in microglia of the spinal cord, demonstrating a link between a peripheral inflammatory stimulus, p-p38 and mTNFa expression in dorsal horn, and pain-related behavior. The observation that IL-10 appeared to significantly block p-p38 and the increase in mTNFa expression while incompletely reducing flinching behavior indicates that the p38-TNFa pathway plays a role in part but not all of the nocisponsive behaviors in the formalin model. IL-10 is a prototypical antiinflammatory cytokine. 34 Systemic administration of IL-10 protein produces an analgesic effect in models of inflammatory pain assessed by writhing in response to intraperitoneal administration of acetic acid or zymosan, 35 or by knee incapacitation following intra-articular injection of zymosan. 35 IL-10 protein also reduces pain-related behaviors in a model of spinal pain caused by intraspinal injection of quisqualic acid. 36 There is also extensive evidence that using viral vectors or naked plasmids intrathecally results in expression of IL-10 by meningeal cells, effectively reducing pain-related behaviors in several models of peripheral neuropathic pain. 15, 16 The current study extends these observations regarding the pain-relieving effects of IL-10 to a model of inflammatory pain, in which vector-mediated delivery of the gene product is achieved through gene transfer to DRG neurons, and implicate expression of spinal mTNFa in the phenomenon of chronic inflammatory pain.
HSV has unique advantages as a gene transfer vector to peripheral sensory neurons located in the DRG. Transgene products expressed from DRG neurons can provide local effects to modulate neuroinflammatory responses at the level of the central terminations of afferent axons in the spinal cord, and in the peripheral distribution of those same axons without requiring amounts of the transgene product that would alter the systemic immune response. This may prove to be of potential benefit in the adaptation of these strategies to the treatment of chronic pain in patients.
Materials and methods

Vectors
Two viral vector constructs were employed in this study. QHIL10 contains IL-10-HA under the control of the HCMV IEp. Control vector QHGFP is identical to QHIL10, but contains the GFP gene product in place of IL-10-HA (Figure 1 ). Full-length IL-10 was amplified from a cDNA library prepared from total RNA extracted from rat brain and cloned into BamHI-cut HCMVpolyA/SASB3-16. The HCMV-polyA/SASB3-16 plasmid was cotransfected with the nonreplicating HSV-recombinant UL41E1G6 (kindly provided by Dr Joseph Glorioso, University of Pittsburgh) into 7b cells. Three runs of extraction were performed to select clear plaques and the identity of the insert confirmed by PCR followed by DNA sequencing.
Cell culture
Microglia cells derived from neonatal rat brain 19 (HAPI cells, provided by JR Connor Pennsylvania State University College of Medicine, Hershey, PA, USA) were grown in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum. In the LPS experiments, HAPI cells were treated with LPS (1 mg ml
À1
, Sigma-Aldrich, St Louis, MO, USA) for 6 h. In some experiments 10 mM of p38 MAPK inhibitor SB202190 (Calbiochem, La Jolla, CA, USA) was added 30 min prior to LPS treatment. DRG from 17-day-old rat embryos were cultured as described previously.
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ELISA
The amount of IL-10 released from transduced HAPI cells or DRG neurons was determined using a commercial IL-10 ELISA kit (R&D Systems, Minneapolis, MN, USA). TNFa released from HAPI cells after induction by LPS was determined using TNFa ELISA kits (R&D Systems).
Western blot
The dorsal quadrant was dissected from L4-L6 spinal cord and homogenized in lysis buffer containing 50 mM Tris, 10 mM NaCl, 1% NP40, 0.02% sodium azide and protease inhibitor cocktail (Sigma-Aldrich) at pH 7.4. Cultured DRG cells and HAPI cells were dislodged from culture plates with a cell scraper and homogenized in the same lyses buffer. Cell lysate and tissue homogenates were sonicated then centrifuged at 15 000 g for 10 min at 4 1C. Medium from DRG cell cultures was centrifuged at 1000 g for 10 min at 4 1C. Ammonium sulfate was added to the supernatant to 35% saturation and centrifuged at 10 000 g for 15 min at 4 1C, and the pellet was collected for analysis. Aliquots containing 20 mg of protein were dissolved in Laemmli buffer and boiled at 95 1C for 5 min, and the proteins separated by 12% Tris-glycine sodium dodecyl sulfate-polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA, USA), transferred to nitrocellulose membranes, blocked and then incubated with primary antibodies at 4 1C. Primary antibodies included an antibody against HA (anti-HA, 1:500; SigmaAldrich), anti-IL-10 (1:1000; R&D Systems), anti-TNFa (1:500; Chemicon International, Temecula, CA, USA or 1:500; R&D Systems) and anti-phospho-p38 and anti-p38 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Peroxidase-coupled secondary antibodies (Calbiochem) were used for amplification and protein bands visualized using X-OMAT AR film (Kodak, Rochester, NY, USA) after chemiluminescence (DuPont NEN, Boston, MA, USA). The membranes were stripped and reprobed with mouse anti-b-actin (1:2000; Sigma-Aldrich) as a loading control. The intensity of each band was determined by quantitative chemiluminescence using a PC-based image analysis system (ChemiDoc XRS System, Bio-Rad Laboratories). 
Semi-quantitative RT-PCR
cDNA prepared from RNA isolated from HAPI cells or rat spinal cord was amplified using following primer sets: b-actin-F (5 0 -CAGTTCGCCATGGATGACGATATC-3 0 ) and b-actin-R (5 0 -CACGCTCGGTCAGGATCTTCA TG-3 0 ) for b-actin, and TNFa-F (5 0 -TCCGAGATGTGG AACTGGCAGAG-3 0 ) and TNFa-R (5 0 -GAGCAATGA CTCCAAAGTAGACCTGC-3 0 ) for TNFa. All reactions involved initial denaturation at 94 1C for 5 min followed by 28 cycles (for b-actin and TNFa) at 94 1C for 30 s, 68 1C for 3 min, followed by 1 cycle at 68 1C for 8 min using a GeneAmp PCR 2700 (Applied Biosystems, Foster City, CA, USA).
Data analysis
Statistical significance of the difference between vectortreated and control animals was determined by one-way analysis of variance with post hoc comparisons where appropriate. Parametric statistics, using the general linear model for repeated measures, were used to identify significant effects of treatment condition on the behavioral measure of neuroinflammatory pain. The results were examined using the software package SPSS 12.0 for Windows (SPSS, Chicago, IL, USA). Data are expressed as mean7standard error of mean (s.e.m.), with P-value less than 0.05 considered significant.
Experimental animals and behavioral analysis
Male Sprague-Dawley rats weighing 200-250 g were used in all experiments. Housing conditions and experimental procedures were approved by the University of Michigan Committee on Use and Care of Animals. Vector QHIL10 or control vector QHGFP was injected subcutaneously (30 ml of vector at a concentration of 1 Â 10 9 PFU per ml) into one hind foot. After 10 days of vector inoculation, 50 ml of 5% formalin was injected subcutaneously into the dorsal surface of the right hind paw. Spontaneous flinching behavior during both acute phase and long-lasting tonic phase was observed. The number of flinches, characterized as a rapid and brief withdrawal or flexion of the injected paw, was counted for 1 min periods at 1-2, 5-6 and 9-10 min, and then at 5-min intervals during the period 10-60 min after injection.
